» Articles » PMID: 36558430

Resveratrol Against Cervical Cancer: Evidence from In Vitro and In Vivo Studies

Overview
Journal Nutrients
Date 2022 Dec 23
PMID 36558430
Authors
Affiliations
Soon will be listed here.
Abstract

Cervical cancer affects many women worldwide, with more than 500,000 cases diagnosed and approximately 300,000 deaths each year. Resveratrol is a natural substance of the class of phytoalexins with a basic structure of stilbenes and has recently drawn scientific attention due to its anticancer properties. The purpose of this review is to examine the effectiveness of resveratrol against cervical cancer. All available in vitro and in vivo studies on cervical cancer were critically reviewed. Many studies utilizing cervical cancer cells in culture reported a reduction in proliferation, cell cycle arrest, and induction of apoptosis. Apart from apoptosis, induction of autophagy was seen in some studies. Importantly, many studies have shown a reduction in the HPV oncoproteins E6 and E7 and increased levels of the tumor suppressor p53 with resveratrol treatment. A few studies examined the effects of resveratrol administration in mice ectopic-xenografted with cervical cancer cells showing reduced tumor volume and weight. Overall, the scientific data show that resveratrol has the ability to target/inhibit certain signaling molecules (EGFR, VEGFR, PKC, JNK, ERK, NF-kB, and STAT3) involved in cervical cancer cell proliferation and survival. Further in vivo experiments and clinical studies are required to better understand the potential of resveratrol against cervical cancer.

Citing Articles

Does Resveratrol Impact Oxidative Stress Markers in Patients with Head and Neck Cancer Receiving Home Enteral Nutrition?.

Lawinski M, Zadka K, Ksepka N, Matin M, Wysocki K, Karkocha D Nutrients. 2025; 17(3).

PMID: 39940362 PMC: 11819975. DOI: 10.3390/nu17030504.


Resveratrol modulates phosphorylation of ERK and AKT in murine cementoblasts during in vitro orthodontic compression.

Negm S, Wolf M, Craveiro R, Schurgers L, Jankowski J, Schneider R BMC Oral Health. 2025; 25(1):226.

PMID: 39939842 PMC: 11823246. DOI: 10.1186/s12903-025-05591-5.


Copper Imparts a New Therapeutic Property to Resveratrol by Generating ROS to Deactivate Cell-Free Chromatin.

Khanvilkar S, Mittra I Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861193 PMC: 11769567. DOI: 10.3390/ph18010132.


Drugs and drug targets for the treatment of HPV-positive cervical cancer.

Burmeister C, Khan S, Prince S Tumour Virus Res. 2024; 19():200309.

PMID: 39709045 PMC: 11733058. DOI: 10.1016/j.tvr.2024.200309.


RNA m6A methylation regulatory mechanism of resveratrol in premature senescence cells.

Zhang X, Zhu C, Zhang L, Tan L, Cheng W, Li M Food Sci Nutr. 2024; 12(11):9238-9251.

PMID: 39619978 PMC: 11606896. DOI: 10.1002/fsn3.4487.


References
1.
Chow H, Garland L, Heckman-Stoddard B, Hsu C, Butler V, Cordova C . A pilot clinical study of resveratrol in postmenopausal women with high body mass index: effects on systemic sex steroid hormones. J Transl Med. 2014; 12:223. PMC: 4243716. DOI: 10.1186/s12967-014-0223-0. View

2.
Alharbi H, Alshehri A, Ahmad M, Guo W . Promising anti- cervical carcinoma and inflammatory agent, Resveratrol targets poly (ADP-ribose) polymerase 1 (PARP-1) induced premature ovarian failure with a potent enzymatic modulatory activity. J Reprod Immunol. 2021; 144:103272. DOI: 10.1016/j.jri.2021.103272. View

3.
Azorin-Ortuno M, Yanez-Gascon M, Vallejo F, Pallares F, Larrosa M, Lucas R . Metabolites and tissue distribution of resveratrol in the pig. Mol Nutr Food Res. 2011; 55(8):1154-68. DOI: 10.1002/mnfr.201100140. View

4.
Zhang P, Li H, Yang B, Yang F, Zhang L, Kong Q . Biological significance and therapeutic implication of resveratrol-inhibited Wnt, Notch and STAT3 signaling in cervical cancer cells. Genes Cancer. 2014; 5(5-6):154-64. PMC: 4104760. DOI: 10.18632/genesandcancer.15. View

5.
Wang Y, Wang J, Liu C, Li M . Silent Information Regulator 1 Promotes Proliferation, Migration, and Invasion of Cervical Cancer Cells and Is Upregulated by Human Papillomavirus 16 E7 Oncoprotein. Gynecol Obstet Invest. 2021; 87(1):22-29. DOI: 10.1159/000520642. View